CBX1 (p25beta) as a Potential Drug Target and Biomarker for Cancer: An Overview

Target Name: CBX1

NCBI ID: G10951

CBX1 (p25beta) as a Potential Drug Target and Biomarker for Cancer: An Overview

Abstract:

CBX1 (p25beta), a 25kDa hydrophobic ribonuclease, is involved in cell cycle-specific regulation of the degradation of nucleolin (p25). In various cancers, the expression level of CBX1 changes and is closely related to disease prognosis and treatment response. This article aims to explore the role of CBX1 in cancer as a potential drug target or tumor biomarker.

1 Introduction

2. Discovery and identification of CBX1

2.1 Overview of CBX1

2.2 Expression and regulation of CBX1

2.3 Clinical significance of CBX1

3. Mechanism of action of CBX1

3.1 CBX1 is involved in cell cycle regulation

3.2 Relationship between CBX1 and p25

3.3 The role of CBX1 in tumors

4. Possibility of CBX1 as a drug target

4.1 Advantages of CBX1 as an anti-tumor drug target

4.2 Challenges of CBX1 as an anti-tumor drug target

4.3 Combination strategies of CBX1 and targeted therapy

5. Application of CBX1 as a tumor biomarker

5.1 CBX1 as a biomarker for early diagnosis of tumors

5.2 CBX1 as a biomarker for tumor prognosis assessment

5.3 Biomarker research on CBX1 and tumor treatment

6 Conclusion

Protein Name: Chromobox 1

Functions: Component of heterochromatin. Recognizes and binds histone H3 tails methylated at 'Lys-9', leading to epigenetic repression. Interaction with lamin B receptor (LBR) can contribute to the association of the heterochromatin with the inner nuclear membrane

More Common Targets